Zimmer Biomet Intrinsic Value – Zimmer Biomet Anticipated to Reveal Q3 Earnings Results on Wednesday, Consensus EPS Estimate at $1.74

🌥️Trending News

Zimmer Biomet ($NYSE:ZBH) is a leading global medical device company that specializes in products and solutions for orthopedic and musculoskeletal healthcare. As anticipation grows for the company’s third quarter earnings results, investors are eagerly awaiting to see if Zimmer Biomet will continue its trend of strong financial performance. The company has consistently reported positive earnings in recent years, with a steady increase in revenue and impressive profit margins. Analysts are predicting that Zimmer Biomet will once again exceed expectations, with a consensus EPS estimate of $1.74 for the third quarter. The expected strong performance is attributed to both organic growth and recent acquisitions made by the company. One of the key factors driving Zimmer Biomet’s success is its commitment to innovation. The company invests heavily in research and development, constantly striving to improve its current products and develop new solutions to meet the evolving needs of patients and healthcare professionals.

This dedication to innovation has helped Zimmer Biomet maintain its position as a leader in the medical device industry. In addition to its financial performance, Zimmer Biomet has also made strides in the areas of sustainability and corporate responsibility. The company has implemented initiatives to reduce its environmental impact, increase diversity and inclusivity within its workforce, and support local communities through charitable giving and volunteerism. Overall, Zimmer Biomet’s anticipated Q3 earnings results highlight the company’s strength and resilience in the medical device market. With a solid track record of performance and a commitment to innovation and corporate responsibility, Zimmer Biomet is well-positioned for continued success in the future.

Earnings

Zimmer Biomet, a leading global medical technology company, is set to release its third quarter earnings results on Wednesday. Analysts predict that the company will report a consensus EPS (earnings per share) estimate of $1.74 for the quarter. In the previous quarter, Zimmer Biomet reported its earnings for the fourth quarter of fiscal year 2023, ending on December 31, 2021. The company generated a total revenue of 1777.2 million USD, but suffered a loss of 84.0 million USD in net income. This was a decrease of 2.6% in total revenue compared to the same period in the previous year.

However, despite this slight decline in revenue, Zimmer Biomet has shown consistent growth over the past three years. In fact, the company’s total revenue has increased from 1777.2 million USD to 1940.1 million USD in the last three years. This is a positive trend for the company and could indicate strong performance in the upcoming quarter. Investors and analysts will be closely watching Zimmer Biomet’s earnings results to gain insight into the company’s financial health and potential future growth. The EPS estimate of $1.74 is based on analysts’ predictions and will serve as a benchmark for the company’s performance. Any deviation from this estimate, whether positive or negative, could have an impact on the stock price. Overall, the release of Zimmer Biomet’s Q3 earnings results will be an important event for the company and its stakeholders. It will provide valuable information on the company’s financial performance and its ability to continue its growth trajectory. Investors and analysts will be eagerly awaiting the results and using them to make informed decisions about the company’s future prospects.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Zimmer Biomet. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Zimmer Biomet. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Zimmer Biomet. More…

Key Ratios Snapshot

Some of the financial key ratios for Zimmer Biomet are shown below. More…

Stock Price

This slight gain in stock value can be attributed to the anticipation surrounding the company’s upcoming third quarter earnings results, which are set to be revealed on Wednesday. Investors and analysts are eagerly awaiting ZIMMER BIOMET‘s earnings report, with the consensus EPS (earnings per share) estimate currently set at $1.74. This figure represents the average of all analyst predictions for the company’s earnings per share for the third quarter. It will serve as an important benchmark for evaluating the company’s financial performance and future prospects. ZIMMER BIOMET is a leading medical device company that specializes in products and solutions for the orthopedic, dental, and surgical industries.

In addition to the anticipated earnings results, ZIMMER BIOMET may also provide updates on its recent developments and initiatives during its earnings call on Wednesday. These updates could include progress on new product launches, partnerships, or acquisitions, which may impact the company’s financial performance in the short and long term. Overall, the market’s reaction to ZIMMER BIOMET’s third quarter earnings results will be closely watched by investors and analysts, as it will provide valuable insights into the company’s financial health and future growth potential. With a strong track record of delivering solid financial results, ZIMMER BIOMET is expected to continue its growth trajectory in the coming years. Live Quote…

Analysis – Zimmer Biomet Intrinsic Value

After thorough examination of the financials of ZIMMER BIOMET, I have concluded that the company is currently undervalued by the market. As a result of our analysis here at GoodWhale, we have determined the fair value of ZIMMER BIOMET’s share to be around $127.6. This valuation has been calculated using our proprietary Valuation Line, which takes into account various financial factors and projections. However, on the current market, ZIMMER BIOMET stock is being traded at a price of $103.88. This puts the stock at a significant undervaluation of 18.6% from its fair value. This presents an opportunity for potential investors to acquire shares of ZIMMER BIOMET at a discounted price. Based on our analysis, we believe that ZIMMER BIOMET has strong financials and a promising future. The company has shown consistent growth in revenue and profitability over the years, and its innovative products and strong market position make it a solid investment choice. In conclusion, our analysis shows that ZIMMER BIOMET is currently trading at a price below its fair value, making it an attractive investment opportunity for those looking to add a solid company to their portfolio. We recommend keeping an eye on ZIMMER BIOMET’s stock and considering investing in it at its current undervalued price. More…

Peers

The company operates in two segments, Reconstructive and Dental. It offers knee, hip, shoulder, elbow, hand and wrist, foot and ankle, and biologics products. The company also provides dental prosthetics, including dental implants and CAD/CAM systems; and digital equipment for dentists and laboratories. Zimmer Biomet has a market cap of $24.4 billion and is headquartered in Warsaw, Indiana.

– Alcon Inc ($LTS:0A0D)

Alcon Inc is a global medical company that specializes in eye care products and services. The company’s market cap as of 2022 is 30.09B, and its return on equity is 1.87%. Alcon’s products and services include contact lenses, intraocular lenses, ophthalmic surgical devices, and ophthalmic pharmaceuticals. The company has a presence in over 100 countries and serves customers in the retail, wholesale, and government sectors.

– Sonova Holding AG ($LTS:0QPY)

Sonova Holding AG is a Swiss manufacturer of hearing aids. The company was founded in 1947 and is headquartered in Zurich, Switzerland. As of 2020, Sonova Holding AG had a market cap of 15.37 billion Swiss francs and a return on equity of 18.9%. The company’s products are sold under the brand names Phonak, Unitron, and Advanced Bionics. Sonova Holding AG’s products are available in more than 100 countries.

– Tandem Diabetes Care Inc ($NASDAQ:TNDM)

Tandem Diabetes Care Inc is a medical device company that develops, manufactures and sells insulin pumps for people with diabetes. The company has a market cap of $2.56 billion and a return on equity of -8.79%. Tandem’s products include the t:slim X2 insulin pump, the t:flex insulin pump, and the t:slim G4 insulin pump. The company also offers the t:lock Connectivity System, a cloud-based software platform that allows users to manage their diabetes devices and data.

Summary

Zimmer Biomet, a leading medical device company, is set to release its third quarter earnings on October 30th. The consensus estimate for earnings per share is $1.74. Investors will be closely watching these results, as they have faced challenges in recent quarters due to product recalls and supply chain issues. Analysts will also be analyzing revenue growth and profit margins, as well as any updates on new product launches and strategic partnerships.

Additionally, with the ongoing trade war and potential impact on global markets, investors will be interested in hearing the company’s outlook for the remainder of the year.